145 related articles for article (PubMed ID: 23784744)
21. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
Taha MO; Bustanji Y; Al-Ghussein MA; Mohammad M; Zalloum H; Al-Masri IM; Atallah N
J Med Chem; 2008 Apr; 51(7):2062-77. PubMed ID: 18324764
[TBL] [Abstract][Full Text] [Related]
22. Anti-obesity effects of 3-hydroxychromone derivative, a novel small-molecule inhibitor of glycogen synthase kinase-3.
Lee S; Yang WK; Song JH; Ra YM; Jeong JH; Choe W; Kang I; Kim SS; Ha J
Biochem Pharmacol; 2013 Apr; 85(7):965-76. PubMed ID: 23337568
[TBL] [Abstract][Full Text] [Related]
23. New insights into the autoinhibition mechanism of glycogen synthase kinase-3beta.
Ilouz R; Pietrokovski S; Eisenstein M; Eldar-Finkelman H
J Mol Biol; 2008 Nov; 383(5):999-1007. PubMed ID: 18793648
[TBL] [Abstract][Full Text] [Related]
24. Synthesis and biological evaluation of 3-substituted 2-oxindole derivatives as new glycogen synthase kinase 3β inhibitors.
Lozinskaya NA; Babkov DA; Zaryanova EV; Bezsonova EN; Efremov AM; Tsymlyakov MD; Anikina LV; Zakharyascheva OY; Borisov AV; Perfilova VN; Tyurenkov IN; Proskurnina MV; Spasov AA
Bioorg Med Chem; 2019 May; 27(9):1804-1817. PubMed ID: 30902399
[TBL] [Abstract][Full Text] [Related]
25. Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
Khanfar MA; Hill RA; Kaddoumi A; El Sayed KA
J Med Chem; 2010 Dec; 53(24):8534-45. PubMed ID: 21082766
[TBL] [Abstract][Full Text] [Related]
26. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.
Zhang HC; Boñaga LV; Ye H; Derian CK; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2007 May; 17(10):2863-8. PubMed ID: 17350261
[TBL] [Abstract][Full Text] [Related]
27. [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].
Liu SN; Shen ZF
Yao Xue Xue Bao; 2007 Dec; 42(12):1227-31. PubMed ID: 18338632
[TBL] [Abstract][Full Text] [Related]
28. The Impact of Chronic Glycogen Synthase Kinase-3 Inhibition on Remodeling of Normal and Pre-Diabetic Rat Hearts.
Huisamen B; Hafver TL; Lumkwana D; Lochner A
Cardiovasc Drugs Ther; 2016 Jun; 30(3):237-46. PubMed ID: 27180786
[TBL] [Abstract][Full Text] [Related]
29. Evidence for a new binding mode to GSK-3: allosteric regulation by the marine compound palinurin.
Bidon-Chanal A; Fuertes A; Alonso D; Pérez DI; Martínez A; Luque FJ; Medina M
Eur J Med Chem; 2013 Feb; 60():479-89. PubMed ID: 23354070
[TBL] [Abstract][Full Text] [Related]
30. Glycogen synthase kinase-3beta inhibition preserves hematopoietic stem cell activity and inhibits leukemic cell growth.
Holmes T; O'Brien TA; Knight R; Lindeman R; Shen S; Song E; Symonds G; Dolnikov A
Stem Cells; 2008 May; 26(5):1288-97. PubMed ID: 18323411
[TBL] [Abstract][Full Text] [Related]
31. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
32. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
33. Identification of small molecules that inhibit GSK-3beta through virtual screening.
Kang NS; Lee GN; Kim CH; Bae MA; Kim I; Cho YS
Bioorg Med Chem Lett; 2009 Jan; 19(2):533-7. PubMed ID: 19081248
[TBL] [Abstract][Full Text] [Related]
34. Elucidating substrate and inhibitor binding sites on the surface of GSK-3β and the refinement of a competitive inhibitor.
Licht-Murava A; Plotkin B; Eisenstein M; Eldar-Finkelman H
J Mol Biol; 2011 Apr; 408(2):366-78. PubMed ID: 21354422
[TBL] [Abstract][Full Text] [Related]
35. 6-(4-Pyridyl)pyrimidin-4(3H)-ones as CNS penetrant glycogen synthase kinase-3β inhibitors.
Uehara F; Shoda A; Aritomo K; Fukunaga K; Watanabe K; Ando R; Shinoda M; Ueno H; Kubodera H; Sunada S; Saito K; Kaji T; Asano S; Eguchi J; Yuki S; Tanaka S; Yoneyama Y; Niwa T
Bioorg Med Chem Lett; 2013 Dec; 23(24):6928-32. PubMed ID: 24094818
[TBL] [Abstract][Full Text] [Related]
36. Prediction of binding affinity of 1,2-diphenyline ketone analogues at adenosine triphosphate binding site of glycogen synthase kinase-3β: a molecular docking and dynamic simulation study.
Dinakar S; Gurubarath M; Dhananjayan K
J Biomol Struct Dyn; 2023 Jul; 41(11):4847-4862. PubMed ID: 35543239
[TBL] [Abstract][Full Text] [Related]
37. Discovery of novel 2-(4-aryl-2-methylpiperazin-1-yl)-pyrimidin-4-ones as glycogen synthase kinase-3β inhibitors.
Kohara T; Nakayama K; Watanabe K; Kusaka SI; Sakai D; Tanaka H; Fukunaga K; Sunada S; Nabeno M; Saito KI; Eguchi JI; Mori A; Tanaka S; Bessho T; Takiguchi-Hayashi K; Horikawa T
Bioorg Med Chem Lett; 2017 Aug; 27(16):3733-3738. PubMed ID: 28712706
[TBL] [Abstract][Full Text] [Related]
38. 3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3β inhibitors.
Akhtar M; Bharatam PV
Chem Biol Drug Des; 2012 Apr; 79(4):560-71. PubMed ID: 22168279
[TBL] [Abstract][Full Text] [Related]
39. Synthesis of Coumarin Derivatives as Versatile Scaffolds for GSK-3β Enzyme Inhibition.
Francisco CS; Javarini CL; de S Barcelos I; Morais PAB; de Paula H; de S Borges W; Neto ÁC; Lacerda V
Curr Top Med Chem; 2020; 20(2):153-160. PubMed ID: 31648640
[TBL] [Abstract][Full Text] [Related]
40. Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice.
Wang Y; Lam JB; Lam KS; Liu J; Lam MC; Hoo RL; Wu D; Cooper GJ; Xu A
Cancer Res; 2006 Dec; 66(23):11462-70. PubMed ID: 17145894
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
